Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgeryPhysical activity and genetic predisposition to obesity in a multiethnic longitudinal studyVariation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) studyEffects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second StrokesAspirin and extended-release dipyridamole versus clopidogrel for recurrent strokeDevelopment of a semi-quantitative food frequency questionnaire for use in United Arab Emirates and Kuwait based on local foodsNutrient estimation from an FFQ developed for a Black Zimbabwean populationResource Effective Strategies to Prevent and Treat Cardiovascular DiseaseFood Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report From the Workshop Convened by the World Heart Federation.Rationale and design of the Primary pREvention strategies at the community level to Promote Adherence of treatments to pREvent cardiovascular diseases trial number (CTRI/2012/09/002981)Sharing evidence on humanitarian reliefEffects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) studyOral anticoagulant therapy in patients with coronary artery diseaseLong-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extensionImpact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureAspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular eventsBenefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groupsBenefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) studyUnfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trialsEffects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic reviewEarly and late effects of clopidogrel in patients with acute coronary syndromesOral anticoagulants in patients with coronary artery diseaseShort- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary interventionRelationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparinImpact of ramipril on the circadian periodicity of acute myocardial infarctionBenefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) TrialEffects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevationOral anticoagulant and antiplatelet therapy and peripheral arterial diseaseRationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patientDabigatran versus warfarin in patients with atrial fibrillationThe role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trialObesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control studyEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyGenetic determinants of dabigatran plasma levels and their relation to bleedingLipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control studyHomocysteine lowering with folic acid and B vitamins in vascular diseaseIn a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular eventsDesigning and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomesHomocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication biasBeta adrenergic blokade in myocardial infarction
P50
P58
Q24245983-69905C37-ADFC-4396-91E5-5D6CFE7FE83DQ24289286-3135D27E-17A3-4748-8B7B-B803D91765DDQ24601415-375CBDC1-2ED4-4E4F-92A8-00365A1B4D21Q24645205-B6C5B3B0-4173-4519-B661-56047B77CD6AQ24646522-5EED7FE7-D268-452F-AB49-1826A2C7DD9BQ24814871-999154B3-8A25-40D1-AF40-14138BD5EB7BQ25257005-7AFF0699-AA63-4E4D-80E3-C6ADEE15E2A9Q26768304-34F31D09-74FA-4CB7-B8DA-A001F085883BQ26782788-5252739C-1A0C-439B-925E-E1B387821452Q26859060-F1932CD7-EC30-45DC-9C91-DFAB58379CD1Q28002307-009A8808-89CF-4FC9-9D08-42CC7EBDA969Q28165412-2F371C18-97C0-485F-8AEE-CFA88A195392Q28168987-AE87409B-93D6-4889-857A-55B572111898Q28189678-8CF5B7CA-DF0F-443E-80DA-408D3A78D71DQ28192602-86A90D80-0F56-4792-B814-717FD6AF2316Q28192726-A8C4254A-98AA-4236-8742-814478402826Q28193817-BFEFEF2A-F9B6-49E9-9DA8-6D33E71AC5DEQ28193835-D41405E2-643A-4175-82E3-3ECACC4F9AF8Q28193910-1FF9D796-7BEF-4293-9912-5F530D39F405Q28193960-98D5786B-8095-47B5-9A20-9E9A7ED2B949Q28195029-EF6438FC-5C5C-4EF2-ADBA-F40483FE29D8Q28195427-86CE43FB-A835-4DA9-A0B0-93D580307172Q28195429-8BA19E73-4429-4FEE-B890-9E3E95D90E19Q28196403-9EABFFC6-7A3D-40F6-99F5-F8D424BB6BF5Q28200411-D7088903-9773-4C7C-B063-3A58A5697B48Q28211092-0DDDB398-6EB5-4AB0-94C4-66B8837ACDA0Q28213755-252AA4D2-2A74-4E69-B89D-0EDF80232DBDQ28218519-C26A1B4C-AFCC-4323-A835-7EB9CB329F29Q28219951-76081E50-FCB3-47E4-97FE-2734003F4B93Q28256895-10A72B76-B29C-47C5-B8D3-03DE69158DA0Q28267043-FFF7FBAD-169F-433D-A1A5-979CDA7A2EFEQ28280445-D7F89C28-902C-4F6F-85C2-A6D2C288CC1EQ28281870-4D3FA079-A948-48DF-9246-4275FD0265A9Q28286777-3B8EFD08-25A1-494D-9117-CFA9E2F17072Q28287744-DAB26061-2799-4CAF-B62B-E0E27E1C8DA1Q28301516-F2CC0DE8-FB4E-4307-B057-54D7C00B0355Q28476590-68243B76-7C8E-47E4-AE75-59CC20B0F119Q28730540-6C064A6E-C9A6-41D3-8316-7056F642F72BQ28731901-1068AEFA-62E3-46FE-AF31-B53D481E84A3Q28912127-98a9e4ae-4b32-cd00-ecaf-a5aa895d302a
P50
subject
description
Canadian physician
@en
Canadian physician
@en-ca
Canadian physician
@en-gb
Indiaas cardioloog
@nl
Kanada arst
@et
dochtúir Ceanadach
@ga
indisch-kanadischer Kardiologe und Epidemiologe
@de
medic canadian
@ro
metge canadenc
@ca
mjek kanadez
@sq
name
Salim Yusuf
@ast
Salim Yusuf
@ca
Salim Yusuf
@de
Salim Yusuf
@en
Salim Yusuf
@es
Salim Yusuf
@fr
Salim Yusuf
@ga
Salim Yusuf
@nl
Salim Yusuf
@sl
type
label
Salim Yusuf
@ast
Salim Yusuf
@ca
Salim Yusuf
@de
Salim Yusuf
@en
Salim Yusuf
@es
Salim Yusuf
@fr
Salim Yusuf
@ga
Salim Yusuf
@nl
Salim Yusuf
@sl
prefLabel
Salim Yusuf
@ast
Salim Yusuf
@ca
Salim Yusuf
@de
Salim Yusuf
@en
Salim Yusuf
@es
Salim Yusuf
@fr
Salim Yusuf
@ga
Salim Yusuf
@nl
Salim Yusuf
@sl
P166
P1006
P214
P227
P244
P269
P1006
P166
P19
P21
P213
0000 0000 7695 6691
P214
P227
P244
no2002044258
P269
P27
P31
P496
0000-0003-4776-5601
P569
1952-11-26T00:00:00Z
P691
nlk20040153098